A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction.
Authors
Valle, Juan WArmstrong, Anne C
Newman, C
Alakhov, V
Pietrzynski, G
Brewer, Julie
Campbell, S
Corrie, P
Rowinsky, E K
Ranson, Malcolm R
Affiliation
Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie.nhs.ukIssue Date
2011-10
Metadata
Show full item recordAbstract
To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients andCitation
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. 2011, 29 (5):1029-37 Invest New DrugsJournal
Investigational New DrugsDOI
10.1007/s10637-010-9399-1PubMed ID
20179989Type
ArticleLanguage
enISSN
1573-0646ae974a485f413a2113503eed53cd6c53
10.1007/s10637-010-9399-1